This study first demonstrated the capacity to selectively target leukemia cells using oxidative ferrotherapy by the delivery of ferumoxytol.814 Shen et al. described a therapeutic system (HDL-AuNPs-BMS) for AML that utilized AuNPs and targeted the AML-promoting factor fatty acid-binding protein 4 using BMS309403 (BMS), a small molecule with selective inhibition properties. Here, FABP4 is linked to acute myeloid leukemia.